Jeff Yass’s Arcadia Biosciences RKDA Stock Holding History

Jeff Yass’s Portfolio RKDA Stock Details RKDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-526	Closed	-$21K	–	13974
2022 Q2	$21K	Buy	526 +81	+18%	+$3.73K	﹤0.01%	12357
2022 Q1	$25K	Sell	445 -123	-22%	-$5.87K	﹤0.01%	12563
2021 Q4	$24K	Sell	568 -521	-48%	-$34K	﹤0.01%	12793
2021 Q3	$90K	Sell	1,089 -2,722	-71%	-$255K	﹤0.01%	12119
2021 Q2	$452K	Sell	3,811 -12,578	-77%	-$1.37M	﹤0.01%	9823
2021 Q1	$1.8M	Buy	+16,389	New	+$2.01M	﹤0.01%	6171

Other funds holding RKDA

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BWM

Bullock Wealth Management Bloomington, Indiana $231M AUM

Jeff Yass's RKDA Position: Q2 2026 in Review

Jeff Yass sold out of Arcadia Biosciences (RKDA) in Q2 2026, closing a stake of 12,614 shares — an estimated $17.4K sold.

Jeff Yass first reported a position in RKDA in Q3 2018 and held it in 11 quarters. The position peaked at $461K in Q4 2020. 18 funds tracked by Wall St. Rank hold RKDA as of Q2 2026.

Jeff Yass reported no remaining Arcadia Biosciences position as of Q2 2026 after selling out during the quarter.
Jeff Yass sold 12,614 Arcadia Biosciences shares in Q2 2026, an estimated $17.4K.
Jeff Yass first reported a position in Arcadia Biosciences in Q3 2018 and held it in 11 quarters.
Jeff Yass's Arcadia Biosciences position peaked at $461K in Q4 2020.
18 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.